Trial Information

Summary: Mild to Moderate Plaque-type Psoriasis

The primary objectives of this study are to evaluate the safety and efficacy of EF Calcipotriene Foam compared to another type of foam in subjects with plaque-type psoriasis.

Study drug and study procedures will be made available to you at no cost.

To qualify, you must:

• Be at least 12 years old
• Have mild to moderate plaque-type psoriasis

You will not qualify if you:

• Are pregnant or breast-feeding
• Have a known allergy or other adverse reaction to calcipotriene or other vitamin D analogs
• Have used non-biologic systemic anti-psoriatic therapy (e.g., corticosteroids, PUVA, UVB, retinoids, methotrexate, cyclosporine, other immunosuppressive agents) or biologic therapy (e.g., alefacept, etanercept, efalizumab) within the last 4 weeks.
• Have participated in a clinical drug study within the last 4 weeks

If you would like to learn more about participating in this study, please send an e-mail message using the form below.